US Senate passes psoriasis resolution

6 August 2006

The US Senate has passed Senate Resoltuion 420 (S Res 420), bipartisan legislation calling for improvements in treatment and access to care for individuals with psoriasis and psoriatic arthritis. Senator Gordon Smith (Republican, Oregon), lead sponsor of the resolution, was joined by Senator Frank Lautenberg (Democrat, New Jersey) in leading the effort, supported by other senators.

The resolution recognizes that psoriasis and psoriatic arthritis can be painful, debilitating diseases that can significantly and adversely impact quality of life. Millions of people hold misconceptions about psoriasis, and it remains an often misunderstood disease. The resolution draws attention to the seriousness of psoriasis, the importance of early diagnosis and proper treatment, and the need for public awareness about psoriasis.

Through passage of the resolution, the Senate is encouraging the federal government to expand its psoriasis research efforts, including the psychological and physical effects of the disease. The Senate resolution also supports efforts to increase access to treatments for individuals living with psoriasis and psoriatic arthritis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight